arrow
M

Manuel Hernández-Guerra

Hospital Universitario de Canarias
H指数:39
被引数:6,128

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Revisiting Ferritin-IgG Score to Predict Complete Biochemical Response in Autoimmune Hepatitis

重新评估铁蛋白-IgG评分以预测自身免疫性肝炎的完全生化反应

2026-09-290
OAAI
Improved appropriateness of electronic consultations in primary care with ongoing liver disease education

通过持续的肝病教育提升初级保健中电子会诊的适宜性

2025-12-080
PRE
Role of obesity and estrogen deficiency in non-alcoholic fatty liver disease: Insights from a mouse model

肥胖和雌激素缺乏在非酒精性脂肪肝中的作用:来自小鼠模型的见解

2025-10-010
OA
Relink Programmes: Impact of Reengagement on Linkage to Care Across 82 006 People With Hepatitis C

重新连接项目:再参与对接护理对82006名丙型肝炎患者的影响

2025-09-180
PRE
Defining non-invasive criteria for indicating drug therapy in metabolic-associated steatotic liver disease in clinical practice

定义非侵入性标准以在临床实践中指示代谢相关脂肪性肝病中的药物治疗

2025-09-020
PRE
Isolated IgG elevation in patients with persistently normal transaminases does not affect the outcome of autoimmune hepatitis

持续正常转氨酶的自身免疫性肝炎患者中,孤立性IgG升高不影响其预后。

2025-08-290
OAAI
Rivaroxaban to prevent complications of portal hypertension in cirrhosis: The CIRROXABAN study

利伐沙班预防肝硬化门静脉高压并发症:CIRROXABAN研究

2025-07-190
PRE
Measured glomerular filtration rate predicts liver related deaths better than estimated glomerular filtration rate in advanced chronic liver disease

在晚期慢性肝病中,测量的肾小球滤过率比估计的肾小球滤过率更好地预测肝脏相关死亡

2025-02-012
OAAI
Low penetrance of frequent ATP7B mutations explains the low prevalence of Wilson disease. Lessons from real-life registries.

频繁的ATP7B突变的低外显率解释了威尔逊病的低患病率。现实生活中的注册经验教训。

2025-02-010
PRE
Optimization of Ustekinumab Treatment Induction Using a Pharmacokinetic Model in Inflammatory Bowel Disease Patients

在炎症性肠病患者中使用药代动力学模型优化乌司他单抗治疗诱导

2025-01-220
PRE
Usefulness of buccal swab sample genotyping performed at home for blood relatives of patients with alpha-1 antitrypsin deficiency

在家中对 α-1抗胰蛋白酶缺乏症患者的血亲进行颊拭子样本基因分型的有用性

2024-10-300
PRE
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

sofosbuvir/velpatasvir/voxilaprevir在先前接受sofosbuvir/velpatasvir或glecaprevir/pibrentasvir治疗的丙型肝炎患者中的实际效果

2024-05-023
OAAI
Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice

奥贝胆酸治疗对熊果酚无反应的原发性胆汁性胆管炎的纵向结果: 对添加贝特类药物在现实世界实践中的影响进行分层

2024-05-013
OAAI
The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

生化模式定义了与不同组织学和预后相关的MASLD表型

2024-04-151
OAAI
Predictive factors for decompensating events in cirrhotic patients with primary biliary cholangitis under different lines of therapy

不同治疗方式下肝硬化原发性胆汁性胆管炎患者失代偿事件的预测因素

2024-03-065
PRE
Comparative Study of Predictive Models for the Detection of Patients at High Risk of Inadequate Colonic Cleansing

检测结肠清洗不充分高危患者的预测模型的比较研究

2024-01-171
OAAI